![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Bhatia S, Morrison J, Bower T, McGoon M. Pulmonary hypertension in the setting of acquired systemic arteriove-nous fistulas. Mayo Clin Proc 2003; 78: 908–12.
- Clarkson MR, Giblin L, Brown A, Little D, Donohoe J. Reversal of pulmonary hypertension after ligation of a bra-chiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40: E8.
- Beghetti M, Tissot C. Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Grit Care Med 2009; 30: 421–8.
- Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pul-monary hypertension. N Engl J Med 1993; 328: 1732–9.
- Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketel-slegers JM, Naeije R. Bosentan for the prevention of over-circulation-induced experimental pulmonary arterial hyper-tension. Circulation 2003; 107: 1329–35.
- Gibbs J.S. Making a diagnosis in PAH. Eur Respir Rev 2007; 16: 8–12.
- Simonneau G, Robbins IM, Beghetti M, Channick RN, Del-croix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 54: S43–S54.
![Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.]({"type":"image" , "src" : "/sda/112387/JournalAd-TACD-BOEHR-MPU.jpg"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})